Company |
Company |
Value (M) |
Type/product area |
Terms/details |
Date |
APRIL | |||||
Bind Therapeutics Inc. (Cambridge, Mass.) |
Pfizer Inc. (New York) |
ND |
Extended terms of the global collaboration to create nanomedicines that optimize the therapeutic potential of two molecularly targeted cancer drugs in Pfizer's pipeline |
The collaboration was established in April 2013; the companies agreed to an extension of the timeline for the second program through March 2016; the deal includes about $200M in payments, plus low single- to high single-digit royalties |
4/6/15 |
Coherus Biosciences Inc. (Redwood City, Calif.) |
Baxter International Inc. (Deerfield, Ill.) |
$12 |
Amended collaboration to develop and commercialize CHS-0214, a biosimilar of Enbrel (etanercept, Amgen Inc.), for Europe, Canada, Brazil and other markets |
Milestones and funding obligations have been revised; expansion includes select pre-commercialization activities; revised milestones may exceed previous funding obligations by about $12M, and Baxter will buy Coherus stock in a private placement |
4/16/15 |
Infinity Pharmaceuticals Inc. (Cambridge, Mass.) |
Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) |
$52.5 |
Exercised option to buy out future royalty obligations due to Takeda for sales of duvelisib (IPI-145), Infinity's dual inhibitor of phosphoinositide-3 kinase-delta and P13K-gamma in oncology indications |
Infinity paid an exercise fee of $52.5M for the option, purchased in July 2014 from Takeda's Millennium unit for $5M; exercising the option eliminates the future obligation to pay Takeda tiered royalties ranging from 7% to 11% on worldwide net sales of duvelisib in oncology indications |
4/1/15 |
Myriad Genetics Inc. (Salt Lake City) |
Astrazeneca plc (London) |
ND |
Expanded companion diagnostic collaboration for use of Myriad's BRACAnalysis test to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with Lynparza (olaparib) |
Terms were not disclosed |
4/2/15 |
Peptidream Inc. (Tokyo) |
Novartis AG (Basel, Switzerland) |
ND |
Exercised option under a 2012 strategic alliance agreement to obtain a nonexclusive license to Peptidream's Peptide Discovery Platform System technology |
Peptidream will receive multistage up-front technology access payments and will be eligible for development milestones and royalties on related product sales |
4/3/15 |
MAY | |||||
Pharmaxis Ltd. (Frenchs Forest, Australia) |
Boehringer Ingelheim GmbH (Ingelheim, Germany) |
$601 |
Exercised option to in-license PXS4728A from Pharmaxis |
Boehringer Ingelheim is paying $31.4M up front and $570M in milestones tied to approval in nonalcoholic steatohepatitis and chronic obstructive pulmonary disease |
5/19/15 |
Selecta Biosciences Inc. (Watertown, Mass.) |
Sanofi SA (Paris) |
$300 |
Expanded collaboration in which Sanofi is exercising its option to license Selecta's antigen-specific immunotherapy platform for a program targeting celiac disease |
The deal is part of a $900M November 2012 agreement, and Selecta is eligible for up to $300M in milestones and double-digit tiered royalties on net sales |
5/14/15 |
Notes The date indicated refers to the BioWorld Today issue in which the news item can be found. For more information about individual companies and/or products, see Thomson Reuters Cortellis. |